Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data
出版年份 2014 全文链接
标题
Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data
作者
关键词
-
出版物
Expert Opinion On Drug Safety
Volume 13, Issue 8, Pages 1023-1030
出版商
Informa Healthcare
发表日期
2014-06-25
DOI
10.1517/14740338.2014.932348
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence
- (2014) Arrigo FG Cicero et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
- (2014) Frederick J. Raal et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
- (2013) Evan A. Stein et al. CIRCULATION
- Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia
- (2013) Michael J. Koren et al. CIRCULATION
- Is mipomersen ready for clinical implementation? A transatlantic dilemma
- (2013) Barbara Sjouke et al. CURRENT OPINION IN LIPIDOLOGY
- PCSK9 inhibitors
- (2013) Michel Farnier CURRENT OPINION IN LIPIDOLOGY
- The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease
- (2013) Anja Vogt et al. EXPERT OPINION ON PHARMACOTHERAPY
- Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk
- (2013) Gregory S. Thomas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Pharmacotherapies for lipid modification: beyond the statins
- (2013) Antonio M. Gotto et al. Nature Reviews Cardiology
- Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin‐Treated Subjects From 3 Data Sources: A Retrospective Analysis
- (2013) Peter H. Jones et al. Journal of the American Heart Association
- Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia
- (2012) Evan A. Stein et al. CIRCULATION
- Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
- (2012) Maartje E. Visser et al. EUROPEAN HEART JOURNAL
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
- (2012) James M. McKenney et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
- (2012) Evan A Stein et al. LANCET
- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- (2012) Evan A. Stein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
- (2012) Eli M. Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
- (2011) Fatima Akdim et al. EUROPEAN HEART JOURNAL
- Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
- (2010) Fatima Akdim et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
- (2010) Frederick J Raal et al. LANCET
- Lessons Learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial
- (2009) Philip Barter AMERICAN JOURNAL OF CARDIOLOGY
- Perspectives on low-density lipoprotein cholesterol goal achievement
- (2009) Alberico L. Catapano CURRENT MEDICAL RESEARCH AND OPINION
- Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia
- (2009) Maartje E. Visser et al. JOURNAL OF LIPID RESEARCH
- Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe
- (2008) Rosie Z Yu et al. CLINICAL PHARMACOKINETICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now